Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03141177 · OUTCOME

Number of Participants Experiencing Adverse Events (AEs)

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma · Source last updated 2026-08-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From first dose to 100 days following last dose (Up to 32 Months)

What was measured

Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame.

Analysis population: All Treated Participants

Groups in this outcome

Treatment A

Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

Treatment B

Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses) Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD

Treatment C

Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment A320
Treatment B50
Treatment C320

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment A319Not reportedNot reportedNot reportedNot reported
Treatment B50Not reportedNot reportedNot reportedNot reported
Treatment C317Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        319
      2. group Id
        OG001
        value
        50
      3. group Id
        OG002
        value
        317
denoms
  1. counts
    1. group Id
      OG000
      value
      320
    2. group Id
      OG001
      value
      50
    3. group Id
      OG002
      value
      320
    units
    Participants
description
Number of participants experiencing various types of any grade adverse events (AEs) during the specified time frame.
groups
  1. description
    Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
    id
    OG000
    title
    Treatment A
  2. description
    Nivolumab 3 mg/kg IV Q3W (x4 doses) + Cabozantinib 40 mg PO QD + Ipilimumab 1 mg/kg IV Q3W (x4 doses) Then Nivolumab 240 mg flat dose IV Q2W + Cabozantinib 40 mg PO QD
    id
    OG001
    title
    Treatment B
  3. description
    Sunitinib 50 mg PO QD for 4 weeks, followed by 2 weeks off, per cycle
    id
    OG002
    title
    Treatment C
param Type
COUNT_OF_PARTICIPANTS
population Description
All Treated Participants
reporting Status
POSTED
time Frame
From first dose to 100 days following last dose (Up to 32 Months)
title
Number of Participants Experiencing Adverse Events (AEs)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice